Stereotaxis (STXS) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
3 Apr, 2026Executive summary
Annual Meeting scheduled for May 14, 2026, at company headquarters in St. Louis, Missouri, with shareholders encouraged to vote on key proposals.
Shareholders of record as of March 16, 2026, are entitled to vote, with a total of 121,182,983 votes possible, including common and Series A Convertible Preferred Stock.
Proxy materials and the 2025 Annual Report are available online, with multiple voting methods provided.
Voting matters and shareholder proposals
Election of three Class I directors to serve until the 2029 Annual Meeting.
Ratification of Ernst & Young LLP as independent registered public accounting firm for fiscal year 2026.
Advisory (non-binding) vote to approve executive compensation (say-on-pay).
Shareholder proposals for the 2027 Annual Meeting must be submitted by December 4, 2026, for inclusion in proxy materials.
Board of directors and corporate governance
Board consists of nine directors in three staggered classes, with detailed biographies and qualifications provided for each.
Board leadership combines CEO and Chairman roles, with a lead independent director facilitating independent oversight.
All directors except David L. Fischel and Dr. Nathan Fischel are considered independent.
Three standing committees: Audit, Compensation, and Nominating & Corporate Governance, each with independent members and written charters.
Code of Conduct and insider trading policy apply to all directors, officers, and employees.
Latest events from Stereotaxis
- Recurring revenue surged 270% on new catheter adoption, with profitability targeted for early 2027.STXS
Q2 2026 - Resale registration for 108M+ shares highlights dilution and integration risks after Robocath deal.STXS
Registration filing - Registers 19.9% of shares for resale post-Robocath acquisition; no proceeds to company.STXS
Registration filing - Robotic magnetic navigation and digital innovation drive safer, scalable endovascular surgery worldwide.STXS
Investor presentation - Regulatory wins, new products, and Robocath deal drive optimism for double-digit 2026 growth.STXS
Q1 2026 - Acquisition accelerates robotic leadership in endovascular care, targeting rapid market growth.STXS
M&A announcement - Vote on director elections, auditor ratification, and executive compensation by May 13, 2026.STXS
Proxy filing - Shelf registration enables up to $150 million in offerings to fund growth, with significant dilution risk.STXS
Registration Filing - Q1 2025 revenue up 9% to $7.5M, driven by recurring revenue and innovation, despite higher net loss.STXS
Q1 2025